Effective April 1, 2023, revised billing guidance from the Palmetto GBA MolDX® program concerning the reimbursement of non-invasive molecular diagnostic tests limits Medicare reimbursement to only one molecular test for a given patient encounter. As such, our OmniGraf dual-biomarker rejection panel is no longer commercially available. We remain committed to providing the most advanced and reliable tests to the transplant community, and we continue to offer TruGraf Kidney and Viracor TRAC as individual tests to ensure that transplant clinicians have access to the most advanced diagnostic tools available.

 

 

TruGraf Kidney logo.

 

Microfluidic gene expression classification of the 120 specific genes that express during subclinical acute rejection.

 

 

 

 

Next-generation sequencing of donor-derived cell-free DNA, analyzing the whole genome (70,000+ SNPs) for evaluating clinical acute rejection.